Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Vibrio vulnificus, a rare "flesh-eating" bacterium, has claimed its first life of 2026 in the US state of Florida, according to state health officials.

Florida health data show that, as of July 30, the state has reported 12 confirmed cases this year, including one death in an elderly person in Palm Beach County. In 2025, Florida recorded 33 Vibrio vulnificus infections and five deaths linked to the bacterium.

What Is Vibrio Vulnificus?

Vibrio vulnificus is a naturally occurring bacterium found in warm saltwater or brackish water, which is a mix of salt and freshwater. It thrives particularly well during the hotter months, which is why infections spike from May through October.

According to the Centers for Disease Control and Prevention (CDC), the bacterium is halophilic, meaning it needs salt to survive.

While rare, the infection can cause necrotizing fasciitis. It is a condition where flesh-eating bacteria could destroy the tissue under the skin and can lead to death in just a few days if left untreated.

How People Get Infected?

The bacterium earned its "flesh-eating" moniker from its ability to cause an infection called vibriosis that damages or "eats away" at skin and tissue.

According to Dr. Norman Beatty, an infectious disease specialist and associate professor at the University of Florida, as reported by WUSF, there are two main ways people typically contract Vibrio vulnificus.

“We can consume it through contaminated shellfish, specifically oysters,” Beatty said. If ingested, the bacteria can cause symptoms like nausea, vomiting, diarrhea, and abdominal cramps.

But the more dangerous and more common route, he explains, is through open wounds. “If someone with a cut or scrape enters brackish or saltwater contaminated with Vibrio vulnificus, the bacteria can enter the body through the skin and cause serious infection,” he warned.

Also read: Rare Tick-Borne Bourbon Virus Case Detected In New York For The First Time

Symptoms To Watch For

Symptoms often appear quickly; sometimes within hours of exposure. Early signs include redness, pain, and swelling around the wound. As the infection progresses, it can cause skin ulcers, blisters, and even tissue death. Systemic symptoms like fever, chills, and low blood pressure may also follow.

“A delay in treatment can lead to serious complications, including amputations or even death,” Dr. Beatty cautioned.

Who’s Most at Risk?

People with weakened immune systems, liver disease, or chronic health conditions are at greater risk of developing severe infections. But Dr. Beatty emphasized that even healthy individuals aren’t immune.

“I’ve seen otherwise healthy people who got a small cut while fishing or kayaking and ended up battling this infection,” he said.

How to Stay Safe?

Read More: Milestone In Kala-Azar Treatment: WHO Updates Treatment Guidelines, Recommends Shorter & Safer Regimens

With summer in full swing and more people spending time in and around water, doctors urge caution. If you have an open wound, avoid wading or swimming in warm seawater or brackish water. If exposure happens accidentally, clean the wound immediately with soap and bottled water. Covering healing wounds with waterproof bandages can also reduce the risk of infection.

If symptoms develop after being in such water or consuming raw seafood, particularly oysters, seek medical attention immediately and inform the doctor of your recent exposure.

A Persistent Health Threat

An average of 100 to 200 cases of vibriosis caused by Vibrio vulnificus are reported in the United States each year, with most of them in Gulf Coast states, according to CDC data. “This is not a bacteria to take lightly. With increased awareness and a bit of caution, we can lower the risk and save lives,” Dr. Beatty said.

US researchers have identified the first known infection caused by Bourbon virus in a man from New York's Long Island, raising concerns that the rare tick-borne virus may have gone undetected for years.

The case, published in the American Journal of Tropical Medicine and Hygiene, suggests that the virus could be circulating more widely in the Long Island region than previously believed.

Because Bourbon virus causes symptoms similar to more common tick-borne illnesses, including Lyme disease, experts believe some infections may have been misdiagnosed.

What Is the Case?

In 2021, 67-year-old Michael Larkin was bitten by two lone star ticks while working outdoors. However, it took about 5 years to get a proper diagnosis.

Because his symptoms resembled those of more common tick-borne illnesses, including Lyme disease, doctors initially treated him with antibiotics. However, since antibiotics do not work against viral infections, his condition worsened and he developed fever, rash, night sweats and debilitating headaches.

The lack of a commercially available diagnostic test further complicated his diagnosis, making it difficult for physicians to identify the virus during the acute stage of illness.

Larkin's illness was confirmed to have been caused by Bourbon virus recently, after he got enrolled in a year-long antibody study, with blood samples collected every three months.

"Now we know the virus can be lethal. On Long Island, at least, we have a lot of lone star ticks," Dr. Luis Marcos, who treated Larkin, told CBS News. "And honestly this may be the very, very tip of the iceberg."

What Is Bourbon Virus?

Bourbon virus is a rare tick-borne virus believed to spread through the bite of infected lone star ticks (Amblyomma americanum).

According to the US Centers for Disease Control and Prevention (CDC), cases have previously been reported in parts of the Midwest, East Coast and Southern United States.

The virus was first identified in 2014 and was named after Bourbon County, Kansas, where it was initially discovered. There is currently no vaccine to prevent Bourbon virus infection and no specific antiviral treatment.

Symptoms of Bourbon Virus

People infected with Bourbon virus have reported symptoms including:

• Fever
• Fatigue
• Rash
• Headache
• Muscle and body aches
• Nausea and vomiting

• Low white blood cell counts
• Low platelet counts

How Does It Spread?

Bourbon virus is believed to spread through the bite of infected lone star ticks. These aggressive ticks are identified by the single white spot—or "lone star"—on the backs of adult females. They are commonly found in wooded areas, brush and tall grass.

Lone star ticks are also known to transmit several other diseases, including:

• Ehrlichiosis
• Tularemia
• Alpha-gal syndrome (red meat allergy)

Could More Cases Be Going Undetected?

The researchers noted that the Bourbon virus is likely more prevalent than we think in New York and other cases are likely not being diagnosed.

Marcos added that the findings highlight the urgent need for improved surveillance, expanded testing and better guidance for healthcare providers.

"Without identifying the cause of an infection, the chances of developing accurate diagnostic tests or effective treatments are minimal," Marcos said. "That is why it is so important to first understand the true impact of the virus in high-risk areas."

How to Prevent The Deadly Infection?

Health experts recommend taking the following precautions:

• Protect yourself from tick bites by avoiding wooded, brushy and grassy areas whenever possible.
• Stay in the center of hiking trails.
• Wear long sleeves and long pants outdoors.
• Treat clothing and gear with 0.5% permethrin.
• Use EPA-registered insect repellents containing ingredients such as DEET.
• Check your body, clothing and pets for ticks after spending time outdoors and remove attached ticks promptly.

Scientists have discovered an Achilles' heel that helps some of the most aggressive cancers escape treatment. The discovery that could pave the way for new targeted therapies against specific drug-resistant tumours.

Researchers at Nanyang Technological University (NTU) Singapore, identified a protein called TEX264 that enables cancer cells to escape the therapeutic effects of a widely used class of targeted cancer drugs known as PARP inhibitors. The study is published in Nature Cell Biology.

What Does This Mean For Drug-Resistant Cancers?

The findings could have positive implications for patients with triple-negative breast cancer, as well as ovarian, prostate, and pancreatic cancers that are treated with PARP inhibitors. These cancers eventually become resistant to the drugs.

"Our findings have identified a new biological process involving TEX264 as a key mechanism of drug resistance in an aggressive form of cancer," said Professor Kristijan Ramadan, who led the research. "We coined this new biological mechanism 'autophagy of DNA lesions', or simply 'nucleophagy'. This makes TEX264 a potential target for future cancer therapies."

Also read: Don't Fear The Biopsy, Fear The Delay

How Do Some Cancers Escape Treatment?

PARP inhibitors work by blocking PARP1, a protein that repairs damaged DNA inside cancer cells. Without this repair system, tumour cells accumulate DNA damage and die. However, many cancers eventually become resistant to this treatment.

The researchers discovered that TEX264 helps remove trapped PARP1 proteins from damaged DNA through a newly identified clean-up process called nucleophagy, allowing cancer cells to continue repairing themselves and escape the treatment. This is the cellular recycling system that makes cancer resistant to treatments.

When scientists blocked TEX264 in experiments, PARP1 remained stuck on DNA, DNA damage accumulated, and the cancer cells became far more vulnerable to therapy.

Also read: US FDA Approves New Blood Test To Screen For Colorectal Cancer

What Are PARP Inhibitors?

They are approved for several cancers, including ovarian, breast, prostate, and pancreatic cancer.

While many patients initially respond well, resistance develops in an estimated 40% to 70% of breast and ovarian cancer cases.

Also read: Scientists Find Rare Contagious Skin Cancer In Fish From US, Canada: Should Humans Worry?

Importance Of This Study

Instead of targeting the DNA repair machinery directly, the new study targets an entirely different weak spot, the cellular cycle that cancer cells exploit to discard damaged repair proteins.

Researchers believe drugs that inhibit TEX264 or block nucleophagy could potentially restore the effectiveness of existing PARP inhibitors, offering a new targeted treatment strategy for patients whose cancers no longer respond to therapy.

The researchers caution that the findings are currently based on laboratory studies, and more research, including clinical trials, will be needed before therapies targeting TEX264 can reach patients.

The promising results adds to growing efforts worldwide to overcome one of oncology's biggest challenges: preventing cancers from evolving resistance to life-saving treatments.